Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 07, 2025 07:00 ET | Source: Akero Therapeutics Inc.

Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025

Post-hoc analyses corroborate previously reported antifibrotic effects of efruxifermin observed in 96-week Phase 2b SYMMETRY trial and indicate potential to reduce risk of disease progression in...
November 06, 2025 07:00 ET | Source: Apyx Medical Corporation

Apyx Medical Corporation Reports Third Quarter 2025 Financial Results

Initiated full U.S. commercial launch of AYON Body Contouring System™ (AYON) at end of Q3 2025, with demand for pre-orders exceeding expectationsSubmitted new 510(k) for AYON for device label...
October 09, 2025 06:01 ET | Source: Akero Therapeutics Inc.

Akero Therapeutics to be Acquired by Novo Nordisk for up to $5.2 Billion

Shareholders to Receive $54 Per Share in Cash and CVR of $6 Per Share Advances Akero’s Mission of Bringing Novel Therapies to Patients with High Unmet Medical Needs SOUTH SAN FRANCISCO, Calif.,...
October 09, 2025 06:00 ET | Source: Novo Nordisk A/S

Novo Nordisk to acquire Akero Therapeutics and its promising phase 3 FGF21 analogue to expand MASH portfolio

Acquisition adds potential first- and best-in-class asset, enhancing Novo Nordisk’s portfolio for treatment of MASH, one of the most prevalent obesity related comorbiditiesAkero Therapeutics’s FGF21...
October 07, 2025 07:00 ET | Source: Akero Therapeutics Inc.

Akero Therapeutics to Present New Data from the Phase 2b SYMMETRY and HARMONY Studies of Efruxifermin at the 76th Annual AASLD The Liver Meeting® 2025

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
September 18, 2025 16:15 ET | Source: Kahn Swick & Foti, LLC

AKERO THERAPEUTICS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Akero Therapeutics, Inc. - AKRO

NEW ORLEANS, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF...
September 18, 2025 08:08 ET | Source: Precedence Research

Electrosurgical Generators Market Size Worth USD 3.78 Billion by 2034 Driven by Rising Chronic Diseases and Surgical Advancements

New York, Sept. 18, 2025 (GLOBE NEWSWIRE) -- According to a new study published by Precedence Research, the global electrosurgical generator market size was valued at USD 1.81 billion in 2024 and is...
September 01, 2025 11:15 ET | Source: Research and Markets

Enterprise Data Protection Solutions Market Report 2025 | Top Players like Microsoft, IBM, and Thales Redefine Enterprise Data Security

Dublin, Sept. 01, 2025 (GLOBE NEWSWIRE) -- The "Enterprise Data Protection (EDP) Solutions - A Global Market Overview" report has been added to ResearchAndMarkets.com's offering.The global...
August 28, 2025 07:00 ET | Source: Akero Therapeutics Inc.

Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
August 21, 2025 08:00 ET | Source: Vaidio

Vaidio Launches 9.1 Release, Accelerates Enterprise Vision AI with Next-Generation Features

Vaidio 9.1 launches with natural language video search, cross-camera tracking, real-time insights, and expanded integrations to accelerate Vision AI.